PROCEPT BioRobotics Highlights Q4 Focus on Platform Scaling and Cash Runway
PROCEPT BioRobotics hosted its Q4 2025 earnings call, focusing on scaling its Aquablation surgical platform and addressing commercial execution hurdles. Management emphasized strategies to expand procedure volumes and manage operating expenses to preserve cash runway into late 2026.
1. Q4 Earnings Call Summary
PROCEPT BioRobotics held its Q4 2025 earnings call to review performance of its Aquablation robotic surgical system, detailing efforts to boost procedure adoption in key markets. Management discussed cost controls and resource allocation measures designed to extend cash runway through late 2026 while pursuing targeted revenue growth.
Related News
META
Meta Secures Tens of Thousands MWh Storage Deals, Cuts 10% Workforce
META•
URBN
Urban Outfitters Q1 Sales Soar 11% to $1.5B, EPS Up 12%
URBN•
AVGO
Nvidia Predicts $91B Q3 Sales, Boosts Dividend and $80B Buyback; Broadcom Poised for AI Inference Growth
AVGO•
TGT
Target Raises Full-Year Sales Outlook to 4% After Q1 Revenue Jumps 6.7%
TGT•
MS
Morgan Stanley to Co-Lead SpaceX’s $1.75T Nasdaq IPO with Four Banks
MS•
Sources
FF